Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
Recruiting · NCT06609876 · Registry updated 2024-12-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC | Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Not applicable | 2024-12-03 | NCT06609876 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chinese PLA General Hospital | 238 |
| Sun Yat-sen University | 606 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Chinese PLA General Hospital | Beijing | China | 6 |